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Identity 
Other names: BRCC4; BRCC45 
HGNC (Hugo): BRE 
Location: 2p23.2 
Local order: According to GeneLoc and NCBI Map 
Viewer, genes flanking BRE are RBKS 2p23.3 
(ribokinase) in the minus strand orientation, and 
RPL23AP34 2p23.2 (ribosomal protein L23a 
pseudogene 34) in the positive strand orientation. 
DNA/RNA 
Description 
The gene spans 448284 bases, telomere to centromere 
orientation. The first exon is non-coding. In humans, 
six transcript variants are produced by alternative 
splicing predominantly at either end of the gene. All 
human cells examined co-express all of the splice 
variants, but at different ratios to one another. The 
major transcript is αa, also known as variant 3 by NCBI 
nomenclature. This transcript encodes the ubiquitous 
383-amino-acid protein, designated by NCBI as protein 
isoform 2 (NP_954661.1) (Ching et al., 2001). 
Functions of all minor transcript variants are 
undetermined. In mice, alternative splicing occurs only 
at the 5' region of the gene. The major transcript is 
variant 5 (NCBI nomenclature), which encodes the 
ubiquitous 383-amino acid protein that is 99% identical 
to human BRE. The minor transcript variants, unlike 
the human counterparts, are expressed differentially 
among tissues. Their functions are undetermined 
(Ching et al., 2003). 
Transcription 
Exon 1 is non-coding; its flanking sequences are 
embedded in a CpG island of 1216 bases long. 
Transcription start varies over the region between 35 to 
112 bases upstream of the last base of exon 1, with the 
most common site at 40 bases upstream. No TATA or 
CAAT box is located within 150 bases upstream of any 
of the transcription start sites. BRE mRNA is expressed 
ubiquitously, and was initially found to be highly 
expressed in brain, and reproductive organs; hence the 
name "BRE" (Li et al., 1995). Subsequent screens 
using human multiple-tissue RNA dot blot and 
Northern blot revealed highest transcript expression in 
adrenal and heart (Miao et al., 2001). 
Pseudogene 
No pseudogene found. 
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Generation of the major transcript variant of human BRE. Human BRE gene (not drawn in scale) is consisted of 15 exons, three of 
which are alternatively spliced. The light green boxes, X - Z, are alternative exons which are not present in the major transcript. The 




BRE is a 383-amino-acid protein of no identifiable 
functional domain by sequence homology. No crystal 
structure of BRE is available. This protein has no 
paralog. The N-terminal region of 333 residues of 
human BRE, which is conserved among vertebrate 
orthologs, has been classified as a single unique 
domain, pfam06113. It has been recently proprosed that 
BRE contains 2 ubiquitin E2 variant (UEV) domains 
(Wang et al., 2009). 
Description 
BRE is an evolutionarily highly conserved protein with 
no homolog within the same species. The major protein 
isoform is 383 amino-acids long. Based on 
bioinformatic analysis, BRE was proposed to have two 
ubiquitin-binding UEV (Ubiquitin E2 variant) domains. 
One was located in the N-terminal region between 
residues 30 and 147. The other one, however, could 
only be located in the isoform encoded by a rare 
transcript variant 1, as the C-terminal one quarter of the 
putative domain is encoded by the alternative exon Y 
(Wang et al., 2009). Thus, it is not clear whether the
remaining putative UEV domain sequence from 
residues 275 to 363 of the major BRE isoform is 
functional. 
Expression 
BRE is ubiquitously expressed. All mammalian cell 
lines examined express high levels of BRE. These cell 
lines include Jurkat, KRC/Y, HeLa, HepG2, HL60, 
MCF7, NIH3T3, NS0, THP-1, and lymphoblastoid 
CB14022 cells. Among mouse tissues, the expression 
levels of BRE detected by Western blot analysis 
showed the following pattern: lungs = spleen = thymus 
> adrenal > testis = kidney > brain > heart = liver. 
Human hepatocytes express little BRE as detected by 
immumnohistochemistry and Western blot analysis 
(Chan et al., 2008). 
Localisation 
BRE is located in cytoplasm and nucleus. 
Function 
DNA-repair and anti-apoptosis via regulation of 
ubiquitination. BRE was shown able to bind K48- and 
K63-linked polyubiquitin chains (Wang et al., 2009). 
BRE and its mouse ortholog are expressed in cytosolic 
and nuclear compartments (Li et al., 2004). In the 
nucleus, BRE is part of the BRCA1-A complex 
involved in DNA repair and maintaining G2/M arrest in 
response to DNA damage. BRCA1-A complex consists 
of BRCA1, BARD1, Abraxas/Abra1/CCDC98, RAP80, 
BRCC36, BRE, and MERIT40/NBA1 (Dong et al., 
2003; Sobhian et al., 2007; Feng et al., 2009; Shao et 
al., 2009; Wang et al., 2009). BRE interacts strongly 
with MERIT40 and is responsible for binding the latter 
to the complex of Abraxas, RAP80 and BRCC36 (Feng 
et al., 2009). BRE may also regulate the K63 
deubiquitinase activity of BRCC36 (Sobhian et al., 
2007). In conjunction with BRCC36, BRE was shown 
to potentiate the E3 activity of BRCA1-BARD1 
complex (Dong et al., 2003). Furthermore, depletion of 
BRE by siRNA sensitized cells to death induced by 
ionizing irradiation (Dong et al., 2003; Feng et al., 
2009). This protein also forms multiprotein BRISC 
(Brcc36 isopeptidase complex) in the cytoplasm. 
BRISC, containing at least 3 proteins, 
FAM175B/ABRO1, BRCC36 and MERIT40/NBA1, in 
addition to BRE, specifically cleaves K63-linked 
polyubiquitin chains (Cooper et al., 2009). It is not 
known whether such cytosolic complex is responsible 
for attenuating apoptotic response emanating from the 
activated death receptors, TNF-R1 and Fas. BRE also 
binds to the cytoplasmic region of TNF-R1 and Fas, as 
well as the death-inducing signaling complex (DISC) 
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during apoptotic induction (Gu et al., 1998; Li et al., 
2004). The anti-apoptotic role of BRE has been shown 
by the increased apoptotic response to TNF-alpha of 
HeLa cell line depleted of BRE by siRNA, and the 
attenuated response of HeLa and Jurkat to TNF-alpha 
and anti-Fas agonist antibody by over-expression of the 
protein. As over-expression of BRE also reduced 
intrinsic apoptotic response induced by stress-related 
and genotoxic stimuli, it has been proposed that the 
death receptor-associating BRE inhibits the recruitment 
of mitochondrial apoptotic machinery, which is 
necessary for amplifying the death-receptor-initiated 
apoptosis of CD95 type II cell types, which include 
HeLa, Jurkat, and hepatocytes (Scaffidi et al., 1998; 
Engels et al., 2000). Ectopic expression of BRE in 
mouse Lewis lung carcinoma cells was shown to 
promote tumor growth in footpad injection model, but 
have no effect on cell proliferation in culture condition 
(Chan et al., 2005). Over-expression of BRE was found 
in 74% of 123 samples of human hepatocellular 
carcinoma, and the protein expression level correlated 
with poor prognosis. Immortalized human cell lines 
also uniformly express high levels of BRE regardless of 
the tissue origin of these cell lines. Transgenic 
expression of BRE in mouse liver attenuated acute 
fulminant hepatitis induced by anti-Fas antibody, and 
promoted diethylnitrosamine-induced, but not 
spontaneous, liver tumors (Chan et al., 2008; Chui et 
al., 2010). Thus, it is likely that BRE over-expression 
enhances tumor survival through its anti-apoptotic 
activity, rather than initiates tumor formation. 
Homology 




According to HapMap genotyped SNP data, there is no 
SNP polymorphism in any of the coding exons of BRE. 
Germinal 
According to the current HapMap_rel27 for all the 4 
populations (CEU, CHB, JPT and YRI), the number of 
nucleotide positions in BRE gene with HapMap 
genotyped SNP is 453. Given the size of BRE gene of 
448284 bases long, the number of bases with SNP fits 
well to the average genome-wide figure of one SNP per 
1000 bases (Dutt and Beroukhim, 2007). It is, however, 
noteworthy that no SNP has been found in any of the 
coding exons. All of the SNPs, except one located in 
the 5' UTR, are present in the introns. Two 
recombination hotspots are located in the introns, one
of which is from position 28271535 to 28276573, 
located between coding exons 7 and 8.  
The other one is from position 28338948 to 28341210, 
located between coding exons 10 and 11. Copy number 
polymorphisms (CNP) involving a large contiguous 
region of 163295 bases encompassing the first 3 coding 
exons and the upstream sequence of the neighbouring 
ribokinase gene and smaller downstream regions have
also been identified (see diagram above) (The 
International HapMap Consortium, 2003). 
Somatic 
One R9L mutation was identified in a lung carcinoma 
cell line, NIH-H2126, and a synonymous mutation 
S182S in a clear cell renal cell carcinoma sample, 
PD2198a. 
Implicated in 
Hepatocellular carcinoma (HCC) 
Note 
Immunohistochemical analysis, supplemented by 
immunoblotting, has revealed overexpression of BRE 
in the tumoral regions of 72% of the 123 human HCC 
samples examined. Non-tumoral liver regions, cirrhotic 
or otherwise, expressed little BRE (Chan et al., 2008). 
Prognosis 
The over-expression levels of BRE correlated with 







No fusion protein reported. 
Oncogenesis 
The transgenic mouse model with liver-specific over-
expression of human BRE showed no enhanced 
spontaneous tumor development, indicating that BRE 
over-expression alone is not tumorigenic. These mice, 
however, showed significant attenuation of liver 
apoptosis induced by injection anti-Fas agonist 
antibody. These findings indicate that the over-
expression of BRE in HCC is related to the anti-
apoptotic activity of the protein which promotes growth 
of the carcinoma (Chan et al., 2008). 
 
Copy number polymorphism (CNP) of BRE gene. Regions with CNP are shown in colored boxes. Blue and red indicate copy loss and 
gain, respectively. Green indicates loss and gain at different segments of the contiguous region. The largest CNP region on the far left 
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spans the first non-coding and the next 3 coding exons (exons 1, 2, 3 and 4) and extends further upstream into the neighboring 
ribokinase gene. The copy gain variant at the far right spans the alternative exon Z. Data obtained from HapMap. 
Recent work on inducing liver carcinoma to the above 
transgenic mice by neonatal injection of 
diethylnitrosamine (DEN) confirmed that BRE over-
expression in the liver could only promote growth of 
the already initiated tumor, rather than on initiating 
tumor formation. Interestingly, the DEN-induced liver 
tumors of the non-transgenic controls also showed up-
regulation of endogenous BRE, suggesting that the 
BRE is important in liver carcinogenesis through its 
anti-apoptotic activity (Chui et al., 2010). 
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